Lupin Launches Generic Apriso in US
Mumbai, Baltimore: Drug Maker Lupin Limited has announced the launch of an authorized generic version of Bausch Health's Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) is indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso® had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.